Phio Pharmaceuticals Corp. (PHIO): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company aims to revolutionize cancer treatment? Phio Pharmaceuticals Corp. (PHIO), a clinical-stage biotechnology company founded in 2011, is focused on developing immuno-oncology therapeutics using its proprietary INTASYL siRNA gene silencing technology to enhance immune cell effectiveness against cancer. But how exactly does Phio Pharmaceuticals plan to make waves in the industry, what's their financial standing, and who's steering the ship? Keep reading to find out!

Phio Pharmaceuticals Corp. (PHIO) History

Phio Pharmaceuticals Corp. Founding Timeline

Year established

Phio Pharmaceuticals Corp. was established in 2011.

Original location

The company is located in Marlborough, MA.

Founding team members

While specific founding team members are not explicitly detailed in the provided search results, the company's leadership and scientific advisory board are mentioned. These include individuals with expertise in RNAi technology and drug development.

Initial capital/funding

Information regarding the initial capital or funding for Phio Pharmaceuticals' establishment is not available in the provided search results.

Phio Pharmaceuticals Corp. Evolution Milestones

Phio Pharmaceuticals Corp. Transformative Moments

• Acquisition of RXi Pharmaceuticals' Assets: This strategic move significantly expanded Phio's intellectual property and technological capabilities in the RNAi therapeutics field, providing a broader foundation for future drug development.

• Focus on INTASYL Platform: Shifting focus to the INTASYL platform marked a strategic pivot towards immuno-oncology, leveraging RNAi technology to enhance adoptive cell therapies and potentially create more effective cancer treatments.

• Clinical Trial of PH-762: Initiation of the Phase 1 clinical trial for PH-762 represented a major step forward in translating preclinical research into clinical application, providing initial insights into the safety and efficacy of their RNAi-based therapeutic approach in humans.

For insights into the company's financial standing, consider this resource: Breaking Down Phio Pharmaceuticals Corp. (PHIO) Financial Health: Key Insights for Investors

Phio Pharmaceuticals Corp. (PHIO) Ownership Structure

Phio Pharmaceuticals Corp. features a mixed ownership structure, encompassing institutional holders, individual insiders, and retail investors, influencing its corporate governance and strategic direction.

Phio Pharmaceuticals Corp.'s Current Status

As of April 2025, Phio Pharmaceuticals Corp. operates as a publicly traded company, listed on the NASDAQ under the ticker symbol PHIO. This status allows the company to raise capital through the issuance of stock and subjects it to regulatory oversight by the Securities and Exchange Commission (SEC).

Phio Pharmaceuticals Corp.'s Ownership Breakdown

The ownership of Phio Pharmaceuticals is distributed among various types of shareholders. The following table summarizes the ownership percentages as of the latest available data from the 2024 fiscal year:

Phio Pharmaceuticals Corp.'s Leadership

The leadership team is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:

• Dr. Robert Bitterman: As the President and CEO, Dr. Bitterman leads the overall strategy and operations of Phio Pharmaceuticals, guiding the company's focus on developing innovative therapies.
• Dr. Gerrit Dispersyn: Serving as the Chief Development Officer, Dr. Dispersyn is crucial in overseeing the clinical development programs and ensuring the pipeline progresses efficiently through clinical trials.
• Ms. Danielle Mondoux: As Chief Financial Officer, Ms. Mondoux is responsible for managing the company's financial strategy, reporting, and investor relations.

Understanding the company's mission is also crucial; explore Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp. (PHIO) Mission and Values

Phio Pharmaceuticals is dedicated to developing innovative therapies using self-delivering RNAi (sd-rxRNA) technology to treat diseases with unmet medical needs. The company focuses on silencing disease-causing genes to improve patient outcomes.

Phio Pharmaceuticals Corp.'s Core Purpose

Official mission statement

To develop innovative therapies based on our proprietary self-delivering RNAi (sd-rxRNA®) technology platform that silence disease-causing genes to address significant unmet medical needs and improve the lives of patients.

Vision statement

While I couldn’t find a formal vision statement for Phio Pharmaceuticals, here's what their actions suggest about their vision:

• Focus on Innovation:

They aim to lead in RNAi-based therapeutics through continuous innovation in their sd-rxRNA technology.

• Addressing Unmet Needs:

They strive to develop treatments for diseases where current options are inadequate.

• Improving Patient Lives:

Ultimately, they want to make a tangible difference in the well-being of patients through their therapeutic solutions.

Company slogan/tagline

While I couldn’t find an official slogan, here are a few ways to think about Phio Pharmaceuticals' tagline, based on what they do:

• Silencing Disease, Delivering Hope.
• RNAi Innovation for a Healthier Future.
• Targeting the Source, Transforming Lives.

To delve deeper into the mission, vision, and core values of Phio Pharmaceuticals, explore this resource: Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp. (PHIO) How It Works

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncotherapeutics using its proprietary self-delivering RNAi (INTASYL™) and DNA (DNAiTx™) therapeutic platforms.

Phio Pharmaceuticals Corp.'s Product/Service Portfolio

Phio Pharmaceuticals Corp.'s Operational Framework

Phio Pharmaceuticals Corp. operates through several key processes to discover, develop, and commercialize its immuno-oncology therapeutics:

• Target Identification and Validation: Identifying specific genes and pathways within the tumor microenvironment that suppress immune responses.
• Therapeutic Design: Utilizing the INTASYL™ and DNAiTx™ platforms to design RNAi and DNA-based therapeutics that can effectively silence or modulate these targets.
• Preclinical Development: Conducting in vitro and in vivo studies to evaluate the safety and efficacy of the therapeutic candidates.
• Clinical Development: Progressing promising candidates into Phase 1, Phase 2, and Phase 3 clinical trials to assess safety, tolerability, and efficacy in human patients.
• Manufacturing: Establishing scalable manufacturing processes to produce the therapeutic products for clinical trials and potential commercialization.
• Partnerships and Collaborations: Collaborating with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of its products.

More insights about company's mission, vision & core values can be found here: Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp.'s Strategic Advantages

• Proprietary Technology Platforms: The INTASYL™ and DNAiTx™ platforms provide a unique advantage in developing self-delivering RNAi and DNA-based therapeutics.
• Targeted Immuno-Oncology Approach: By focusing on modulating the tumor microenvironment, Phio's therapies aim to enhance the effectiveness of other cancer treatments.
• Strong Intellectual Property Portfolio: Phio Pharmaceuticals Corp. has a growing portfolio of patents and patent applications covering its technology platforms and therapeutic candidates.
• Experienced Management Team: A team with experience in drug development, and commercialization.

Phio Pharmaceuticals Corp. (PHIO) How It Makes Money

Phio Pharmaceuticals Corp. is a biotechnology company focused on developing therapies using its self-delivering RNAi (sd-rxRNA) technology platform. The company primarily generates revenue through strategic collaborations, licensing agreements, and potentially, future sales of developed products.

Phio Pharmaceuticals Corp. Revenue Breakdown

As a clinical-stage biopharmaceutical company, Phio Pharmaceuticals' revenue streams are currently centered around collaborations and licensing agreements. Until a product reaches commercialization, these agreements are the primary source of income.

Phio Pharmaceuticals Corp. Business Economics

Phio Pharmaceuticals operates under a business model common to biotechnology companies, focusing on research and development with the goal of creating proprietary drug candidates. Key aspects of their business economics include:

• R&D Investment: A significant portion of their expenditure is allocated to research and development activities, essential for advancing their sd-rxRNA technology and pipeline of drug candidates.
• Partnerships: Strategic alliances and collaborations are crucial for funding and expertise, allowing them to share development costs and risks.
• Intellectual Property: Patents and proprietary technology form the backbone of their value proposition, protecting their innovations and providing a competitive edge.
• Clinical Trials: The costs associated with clinical trials represent a major expense, and the success of these trials is pivotal for attracting further investment and partnerships.

To better understand the company's goals, see Mission Statement, Vision, & Core Values of Phio Pharmaceuticals Corp. (PHIO).

Phio Pharmaceuticals Corp. Financial Performance

Phio Pharmaceuticals' financial performance can be evaluated through the following key points:

• Cash Position: Monitoring their cash reserves is vital, as it indicates their ability to fund ongoing research and development.
• Operating Expenses: Analyzing operating expenses, particularly R&D and administrative costs, provides insight into how efficiently the company is managing its resources.
• Net Loss: As a development-stage company, Phio typically experiences net losses, which are expected until they can commercialize a product or generate substantial revenue through licensing.
• Collaboration Revenue: Revenue from collaboration agreements can vary significantly from period to period, depending on the achievement of milestones and the terms of the agreements.

Phio Pharmaceuticals Corp. (PHIO) Market Position & Future Outlook

Phio Pharmaceuticals is strategically positioned as a biopharmaceutical company focused on developing innovative therapies using self-delivering RNAi (sd-rxRNA®) technology to treat cancers and immune-related diseases. With promising preclinical data and a focus on novel drug development, Phio aims to capture a significant share of the oncology and immunotherapy markets.

Competitive Landscape

The competitive landscape for Phio Pharmaceuticals includes other biotechnology and pharmaceutical companies developing RNAi-based therapeutics and treatments for cancer and immune-related disorders.

Opportunities & Challenges

Phio Pharmaceuticals faces both opportunities and challenges as it advances its pipeline and seeks to establish a stronger market presence.

Industry Position

Phio Pharmaceuticals is an emerging player in the RNAi therapeutics market, focusing on innovative approaches to target gene expression in cancer and immune-related diseases. Its industry standing can be further elaborated as:

• Technology Innovation: Phio's sd-rxRNA® technology offers a unique advantage in delivering RNAi therapeutics directly to cells without the need for additional delivery vehicles.
• Strategic Focus: The company is concentrating its efforts on specific oncology and immune-related targets, aiming to address unmet medical needs and establish a competitive edge.
• Partnership Potential: Phio is actively seeking collaborations with other companies to leverage its technology and expand its pipeline.

For more insights into the investors profile, read this article: Exploring Phio Pharmaceuticals Corp. (PHIO) Investor Profile: Who’s Buying and Why?